Palisade's Phase 1 Study Of PALI-2108 Shows No Treatment Related Adversities, Stock Down

(RTTNews) - Palisade Bio, Inc. (PALI), Tuesday announced data from its first three single ascending dose cohorts in its phase 1 human clinical study for PALI-2108 for the treatment of ulcerative colitis.

PALI-2108 is an orally administered, locally acting colon-specific PDE4 inhibitor prodrug in development.

The ongoing study focused on evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, alongside an open-label study involving a patient cohort with ulcerative colitis.

The preliminary findings revealed that PALI-2108 was safe and well tolerated in the first three cohorts at doses 15 mg, 50 mg, and 150 mg. It also demonstrated delayed release of PDE4 inhibitor active, showing successful colonic bioactivation.

Following the announcement, the company intends to advance towards its planned crossover study to evaluate the effects of food on PK, multiple ascending dose cohorts, and a multiple dose cohort of patients with UC.

Currently, Palisade's stock is dropping 6.82 percent, to $2.32 on the Nasdaq.'